• Something wrong with this record ?

Postauthorization safety study of betaine anhydrous

U. Mütze, F. Gleich, SF. Garbade, C. Plisson, L. Aldámiz-Echevarría, F. Arrieta, D. Ballhausen, M. Zielonka, D. Petković Ramadža, MR. Baumgartner, A. Cano, MC. García Jiménez, C. Dionisi-Vici, P. Ješina, HJ. Blom, ML. Couce, S. Meavilla Olivas,...

. 2022 ; 45 (4) : 719-733. [pub] 20220406

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22025332

Patient registries for rare diseases enable systematic data collection and can also be used to facilitate postauthorization safety studies (PASS) for orphan drugs. This study evaluates the PASS for betaine anhydrous (Cystadane), conducted as public private partnership (PPP) between the European network and registry for homocystinurias and methylation defects and the marketing authorization holder (MAH). Data were prospectively collected, 2013-2016, in a noninterventional, international, multicenter, registry study. Putative adverse and severe adverse events were reported to the MAH's pharmacovigilance. In total, 130 individuals with vitamin B6 nonresponsive (N = 54) and partially responsive (N = 7) cystathionine beta-synthase (CBS) deficiency, as well as 5,10-methylenetetrahydrofolate reductase (MTHFR; N = 21) deficiency and cobalamin C (N = 48) disease were included. Median (range) duration of treatment with betaine anhydrous was 6.8 (0-9.8) years. The prescribed betaine dose exceeded the recommended maximum (6 g/day) in 49% of individuals older than 10 years because of continued dose adaptation to weight; however, with disease-specific differences (minimum: 31% in B6 nonresponsive CBS deficiency, maximum: 67% in MTHFR deficiency). Despite dose escalation no new or potential risk was identified. Combined disease-specific treatment decreased mean ± SD total plasma homocysteine concentrations from 203 ± 116 to 81 ± 51 μmol/L (p < 0.0001), except in MTHFR deficiency. Recommendations for betaine anhydrous dosage were revised for individuals ≥ 10 years. PPPs between MAH and international scientific consortia can be considered a reliable model for implementing a PASS, reutilizing well-established structures and avoiding data duplication and fragmentation.

Alder Hey Children's NHS Foundation Trust Liverpool UK

Ap HP Sorbonne University Reference Center for Adult Neurometabolic Diseases La Pitié Salpêtrière University Hospital Paris France

Centre de Référence des Maladies Héréditaires du Métabolisme CHU La Timone Enfants Marseille France

Centre de Référence des Maladies Héréditaires du Métabolisme Hôpital Jeanne de Flandre Lille France

Department of Clinical Genetics Center for Lysosomal and Metabolic Diseases Erasmus Medical Center Rotterdam Netherlands

Department of Clinical Inherited Metabolic Disorders Birmingham Women's and Children's NHS Foundation Trust Birmingham UK

Department of Pediatrics and Inherited Metabolic Disorders Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Department of Pediatrics Landeskrankenhaus Bregenz Bregenz Austria

Department of Pediatrics University Hospital Centre Zagreb and University of Zagreb School of Medicine Zagreb Croatia

Division of Child Neurology and Metabolic Medicine Centre for Child and Adolescent Medicine University Hospital Heidelberg Germany

Division of Metabolism and Children's Research Center University Children's Hospital University of Zurich Zurich Switzerland

Division of Metabolism Bambino Gesù Children's Hospital IRCCS Rome Italy

Endocrinology and Nutrition Metabolic Congenital Disease H U Ramon y Cajal Madrid Spain

Endocrinology Nutrition and Metabolic Diseases Haut Lévêque Hospital Bordeaux University Bordeaux France

Evelina London Children's Hospital London UK

Inserm UMR_S1163 Institut Imagine Paris France

Instituto de Investigación Santiago de Compostela Spain

Manchester Centre for Genomic Medicine Manchester University Hospitals NHS Trust Manchester UK

Metabolic Department University Children Miguel Servet Hospital Aragon Spain

Necker Hospital APHP Reference Center for Inborn Error of Metabolism and Filière G2M Pediatrics Department University of Paris Paris France

Nephrology and Transplantation MAMEA Reference Center Necker hospital APHP Paris France

Pediatric Unit for Metabolic Diseases Woman Mother Child Department Lausanne University Hospital Lausanne Switzerland

Pediatrics Gastroenterology Hepatology and Nutrition Hospital Sant Joan de Déu Barcelona Spain

Recordati Rare Diseases Puteaux France

Unit of Diagnosis and Treatment of Congenital Metabolic Diseases Service of Neonatology Department of Pediatrics Hospital Clínico Universitario de Santiago CIBERER Health Research Institute of Santiago de Compostela Santiago de Compostela Spain

Unit of Metabolic Disorders Universitary Hospital La Fe Valencia Spain

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025332
003      
CZ-PrNML
005      
20221031100809.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12499 $2 doi
035    __
$a (PubMed)35358327
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mütze, Ulrike $u Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany $1 https://orcid.org/0000000242517257
245    10
$a Postauthorization safety study of betaine anhydrous / $c U. Mütze, F. Gleich, SF. Garbade, C. Plisson, L. Aldámiz-Echevarría, F. Arrieta, D. Ballhausen, M. Zielonka, D. Petković Ramadža, MR. Baumgartner, A. Cano, MC. García Jiménez, C. Dionisi-Vici, P. Ješina, HJ. Blom, ML. Couce, S. Meavilla Olivas, K. Mention, F. Mochel, AAM. Morris, H. Mundy, I. Redonnet-Vernhet, S. Santra, M. Schiff, A. Servais, I. Vitoria, M. Huemer, V. Kožich, S. Kölker
520    9_
$a Patient registries for rare diseases enable systematic data collection and can also be used to facilitate postauthorization safety studies (PASS) for orphan drugs. This study evaluates the PASS for betaine anhydrous (Cystadane), conducted as public private partnership (PPP) between the European network and registry for homocystinurias and methylation defects and the marketing authorization holder (MAH). Data were prospectively collected, 2013-2016, in a noninterventional, international, multicenter, registry study. Putative adverse and severe adverse events were reported to the MAH's pharmacovigilance. In total, 130 individuals with vitamin B6 nonresponsive (N = 54) and partially responsive (N = 7) cystathionine beta-synthase (CBS) deficiency, as well as 5,10-methylenetetrahydrofolate reductase (MTHFR; N = 21) deficiency and cobalamin C (N = 48) disease were included. Median (range) duration of treatment with betaine anhydrous was 6.8 (0-9.8) years. The prescribed betaine dose exceeded the recommended maximum (6 g/day) in 49% of individuals older than 10 years because of continued dose adaptation to weight; however, with disease-specific differences (minimum: 31% in B6 nonresponsive CBS deficiency, maximum: 67% in MTHFR deficiency). Despite dose escalation no new or potential risk was identified. Combined disease-specific treatment decreased mean ± SD total plasma homocysteine concentrations from 203 ± 116 to 81 ± 51 μmol/L (p < 0.0001), except in MTHFR deficiency. Recommendations for betaine anhydrous dosage were revised for individuals ≥ 10 years. PPPs between MAH and international scientific consortia can be considered a reliable model for implementing a PASS, reutilizing well-established structures and avoiding data duplication and fragmentation.
650    _2
$a betain $x škodlivé účinky $7 D001622
650    _2
$a cystathionin-beta-synthasa $7 D003541
650    _2
$a homocystein $7 D006710
650    12
$a homocystinurie $x farmakoterapie $7 D006712
650    _2
$a lidé $7 D006801
650    _2
$a methylentetrahydrofolátreduktasa (NADPH2) $x nedostatek $x genetika $7 D042965
650    _2
$a svalová spasticita $7 D009128
650    12
$a psychotické poruchy $7 D011618
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gleich, Florian $u Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany $1 https://orcid.org/0000000173975640
700    1_
$a Garbade, Sven F $u Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany $1 https://orcid.org/0000000274204757
700    1_
$a Plisson, Céline $u Recordati Rare Diseases, Puteaux, France
700    1_
$a Aldámiz-Echevarría, Luis $u Instituto de Investigación Santiago de Compostela (IDIS), Spain $1 https://orcid.org/0000000306876604
700    1_
$a Arrieta, Francisco $u Endocrinology & Nutrition, Metabolic Congenital Disease, H.U. Ramon y Cajal, Madrid, Spain
700    1_
$a Ballhausen, Diana $u Pediatric Unit for Metabolic Diseases, Woman-Mother-Child Department, Lausanne University Hospital, Lausanne, Switzerland $1 https://orcid.org/0000000329403439
700    1_
$a Zielonka, Matthias $u Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany $1 https://orcid.org/0000000196532914
700    1_
$a Petković Ramadža, Danijela $u Department of Pediatrics, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia
700    1_
$a Baumgartner, Matthias R $u Division of Metabolism and Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland $1 https://orcid.org/0000000292700826
700    1_
$a Cano, Aline $u Centre de Référence des Maladies Héréditaires du Métabolisme, CHU La Timone Enfants, Marseille, France
700    1_
$a García Jiménez, María Concepción $u Metabolic Department, University Children Miguel Servet Hospital, Aragon, Spain $1 https://orcid.org/0000000255633177
700    1_
$a Dionisi-Vici, Carlo $u Division of Metabolism, Bambino Gesù Children's Hospital IRCCS, Rome, Italy $1 https://orcid.org/0000000200073379
700    1_
$a Ješina, Pavel $u Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Blom, Henk J $u Department of Clinical Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands $1 https://orcid.org/0000000152029241
700    1_
$a Couce, Maria Luz $u Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Service of Neonatology, Department of Pediatrics, Hospital Clínico Universitario de Santiago, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
700    1_
$a Meavilla Olivas, Silvia $u Pediatrics, Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain
700    1_
$a Mention, Karine $u Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Jeanne de Flandre, Lille, France
700    1_
$a Mochel, Fanny $u Ap.HP, Sorbonne University, Reference Center for Adult Neurometabolic Diseases, La Pitié-Salpêtrière University Hospital, Paris, France
700    1_
$a Morris, Andrew A M $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK $u Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Trust, Manchester, UK
700    1_
$a Mundy, Helen $u Evelina London Children's Hospital, London, UK
700    1_
$a Redonnet-Vernhet, Isabelle $u Endocrinology, Nutrition and Metabolic Diseases, Haut-Lévêque Hospital, Bordeaux University, Bordeaux, France $1 https://orcid.org/0000000251023814
700    1_
$a Santra, Saikat $u Department of Clinical Inherited Metabolic Disorders, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
700    1_
$a Schiff, Manuel $u Necker Hospital, APHP, Reference Center for Inborn Error of Metabolism and Filière G2M, Pediatrics Department, University of Paris, Paris, France $u Inserm UMR_S1163, Institut Imagine, Paris, France
700    1_
$a Servais, Aude $u Nephrology and Transplantation, MAMEA Reference Center, Necker hospital, APHP, Paris, France $1 https://orcid.org/0000000281658212
700    1_
$a Vitoria, Isidro $u Unit of Metabolic Disorders, Universitary Hospital La Fe, Valencia, Spain
700    1_
$a Huemer, Martina $u Division of Metabolism and Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland $u Department of Pediatrics, Landeskrankenhaus Bregenz, Bregenz, Austria $1 https://orcid.org/000000020590678X
700    1_
$a Kožich, Viktor $u Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000158205277
700    1_
$a Kölker, Stefan $u Division of Child Neurology and Metabolic Medicine, Centre for Child and Adolescent Medicine, University Hospital, Heidelberg, Germany
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 45, č. 4 (2022), s. 719-733
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35358327 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100807 $b ABA008
999    __
$a ok $b bmc $g 1854843 $s 1176622
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 45 $c 4 $d 719-733 $e 20220406 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options